Since its IPO, Compass Therapeutics has been fairly volatile. From it's Covid lows, it had quite a run, gaining over 300% in a fairly short amount of time. There was heavy insider buying and very little short interest. This happened all while the overall market and indices were making the 2022 lows. It has since been on a steep downward trajectory, and I have...
NASDAQ:INMD has fallen more than the overall market in the past month, but it is finally getting back to its longer term trend zone formed from its post-pandemic reversal. I am seeing the support from around $33.25 down to around $32.50. The risk to reward will be there for me under $33. The overall fundamentals haven't changed much, and they continue to grow...
